trending Market Intelligence /marketintelligence/en/news-insights/trending/-5lclm4rshGPd8u-TFJl8g2 content esgSubNav
In This List

Infinity appoints industry veterans to advance development of cancer drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Infinity appoints industry veterans to advance development of cancer drug

Cambridge, Mass.-based Infinity Pharmaceuticals Inc. appointed David Beier to its board.

Beier is a managing director of Bay City Capital, a life science-focused venture capital fund. He is also an adviser to the Parker Institute for Cancer Immunotherapy and has extensive knowledge of healthcare policy, economics and drug pricing, the company said.

Also, the biotechnology company named Marie-Louise Fjällskog as vice president of clinical development.

Fjällskog is an associate professor of Oncology at the Uppsala University, Sweden. She joins Infinity from the Novartis Institute for Biomedical Research, where she served as a clinical program leader for translational clinical oncology, and as the global lead for several immuno-oncology programs.

Infinity also promoted Suresh Mahabhashyam to the position of vice president of safety and risk management.

The company made the appointments as it advances its cancer drug IPI-549. The drug is in early stages of clinical development.